Tag: Abbott

Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial

– A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott’s cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure – The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats – Historically, […]

Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair

– New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve – Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient’s complex tricuspid valve anatomy – TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions […]

Abbott’s XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients

– New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding – XIENCE is the most used drug eluting stent in the world, and European approval for shorter DAPT is supported by two studies that […]

Abbott announces approval in Brazil to use two heart devices that can save the lives of babies and children

The world’s smallest pediatric treatments, developed by Abbott, meet the needs of the most vulnerable patients: babies and children born with congenital heart defects Approval includes use of a pediatric mechanical heart valve and the first minimally invasive device to treat premature and newborn babies with an opening in the […]

Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021

– Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales – Sales growth of 28.7 percent; organic sales growth of 28.4 percent – GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent – Delivered more than 300 million COVID-19 […]

Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device

– New national reimbursement enables access to transcatheter mitral valve repair procedures with MitraClip for people with secondary mitral regurgitation, significantly expanding the eligible patient population ABBOTT PARK, Ill., Jan. 20, 2021 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) […]

FDA Approves Labeling Update for Abbott’s HeartMate 3 Heart Pump for use in Pediatric Patients

– Abbott’s HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure – This life-saving technology provides new treatment option for underserved population ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the […]

ABBOTT LAUNCHES FIRST OPTICAL COHERENCE TOMOGRAPHY VIRTUAL REALITY TRAINING PROGRAM FOR CARDIOLOGISTS

Virtual reality training improved cath lab staff learning engagement by 45% and knowledge retention by 72% 87% of studies show higher medical accuracy in medical practice by those trained with virtual reality ABBOTT PARK, Ill., Dec. 9, 2020 — Abbott today announced the global release of its first virtual reality-based […]

ABBOTT INTRODUCES NEXT-GENERATION 3D CARDIAC MAPPING PLATFORM IN EUROPE AND AUSTRALIA

– The EnSite™ X EP System is a new cardiac mapping system designed from electrophysiologist input to optimize cardiac ablation procedures – System offers electrophysiologists a new platform of options to provide consistent performance, regardless of the patient’s cardiac anatomy ABBOTT PARK, Ill., Nov. 2, 2020 — Abbott today announced it […]